For smoking cessation, should varenicline (Chantix) or bupropion (Zyban) be used as first‑line therapy, and what are the recommended dosing schedules, contraindications, and precautions for each?

Varenicline vs Bupropion for Smoking Cessation

Varenicline should be your first-line pharmacotherapy choice over bupropion for smoking cessation, as it demonstrates superior efficacy in achieving and maintaining abstinence at all time points. 1, 2

Efficacy Comparison

Varenicline consistently outperforms bupropion across multiple timeframes:

• At 12 weeks: Varenicline achieves approximately 25.6% continuous abstinence versus 19.0% with bupropion (OR 1.79,95% CI 1.59-2.02) 2
• At 24 weeks: Varenicline maintains superiority (OR 1.51,95% CI 1.32-1.72) 2
• At 52 weeks: The advantage persists (OR 1.60,95% CI 1.22-2.12) 2

The EAGLES trial (n=8,144), the largest and most recent high-quality study, confirmed varenicline's superior abstinence rates compared to bupropion across both psychiatric and non-psychiatric cohorts 3.

Recommended Dosing Schedules

Varenicline (Chantix)

Initiate 1-2 weeks before quit date 3, 4:

• Days 1-3: 0.5 mg once daily
• Days 4-7: 0.5 mg twice daily
• Week 2-12: 1 mg twice daily (if tolerated)
• Duration: 12 weeks standard; consider extending to 24 weeks for successful quitters to prevent relapse 3, 4

Bupropion (Zyban)

Initiate 1-2 weeks before quit date 3:

• Days 1-3: 150 mg once daily
• Day 4 through week 12: 150 mg twice daily (if tolerated)
• Maximum: 300 mg per day
• Duration: 7-12 weeks; may extend to 6-12 months 3

Contraindications and Precautions

Varenicline Contraindications

• Brain metastases (seizure risk) 3
• Allergy to varenicline 5

Key Precautions:

• Nausea is common (25-40% of patients) but usually mild-to-moderate and diminishes over time 3, 4
• Monitor for neuropsychiatric symptoms (depression, suicidal ideation, agitation), though the EAGLES trial found no significant increase versus placebo 3
• Safe in cardiovascular disease 5, 6
• Safe in stable psychiatric disease with close monitoring 5, 6

Bupropion Contraindications

• Seizure history or risk factors (stroke, brain metastases, eating disorders) 3
• MAO inhibitor use (increased hypertensive reaction risk) 3
• Tamoxifen use (drug interaction) 3
• Closed-angle glaucoma 3

Key Precautions:

• 0.1% seizure risk 3
• Use caution in bipolar disorder, liver/kidney disease 5
• Monitor for neuropsychiatric symptoms (though less concern than varenicline historically) 3
• No increased cardiovascular risk 3

Clinical Decision Algorithm

Start with varenicline UNLESS:

1. Patient has brain metastases → Use bupropion (if no seizure risk) or NRT
2. Patient has seizure history/risk → Use varenicline or NRT
3. Patient on MAO inhibitors or tamoxifen → Use varenicline or NRT
4. Patient cannot tolerate nausea (e.g., active chemotherapy) → Consider bupropion or NRT 3

If first-line therapy fails:

• Switch from varenicline → combination NRT + bupropion 3
• Switch from bupropion → varenicline or combination NRT 3

Important Clinical Pearls

Neuropsychiatric Safety: The EAGLES trial definitively resolved prior black box warning concerns—varenicline and bupropion showed no significant increase in neuropsychiatric adverse events versus nicotine patch or placebo in either psychiatric or non-psychiatric cohorts 3. However, patient education and monitoring remain prudent.

Combination Therapy: While varenicline + bupropion shows promise in some studies, it's not currently recommended as first-line due to increased anxiety and depressive symptoms (7.2% vs 3.1%) 3. Reserve combinations for treatment failures.

Dose Adjustments: For varenicline intolerance, consider reducing to 0.5 mg twice daily or 1 mg once daily—most patients achieve good efficacy at lower doses with fewer side effects 7. For severe renal impairment (CrCl <30 mL/min), start varenicline at 0.5 mg once daily, titrate to 0.5 mg twice daily 4.

Always combine pharmacotherapy with behavioral counseling (minimum 4 sessions over 12 weeks preferred) for optimal outcomes 3.